(Q53871933)

21 May 2018

title

IL-10 promoter haplotype influence on interferon treatment response in multiple sclerosis. (English)

1 reference

21 May 2018

0 references

9

C A Vedeler

1 reference

21 May 2018

Stig Wergeland

1

object named as

S Wergeland

1 reference

21 May 2018

Kjell-Morten Myhr

10

object named as

K-M Myhr

1 reference

21 May 2018

author name string

A Beiske

2

1 reference

21 May 2018

H Nyland

3

1 reference

21 May 2018

H Hovdal

4

1 reference

21 May 2018

D Jensen

5

1 reference

21 May 2018

J P Larsen

6

1 reference

21 May 2018

T H Marøy

7

1 reference

21 May 2018

A-I Smievoll

8

1 reference

21 May 2018

publication date

1 March 2005

1 reference

21 May 2018

European Journal of Neurology

published in

1 reference

21 May 2018

volume

12

1 reference

21 May 2018

issue

3

1 reference

21 May 2018

page(s)

171-175

1 reference

21 May 2018

Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Interleukin 10 secretion in relation to human IL-10 locus haplotypes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Rating neurologic impairment in multiple sclerosis: An expanded disability status scale (EDSS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Promoter polymorphism of IL-10 and severity of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Interferon-alpha2a reduces MRI disease activity in relapsing-remitting multiple sclerosis. Norwegian Study Group on Interferon-alpha in Multiple Sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Multiple sclerosis is associated with an imbalance between tumour necrosis factor-alpha (TNF-alpha)- and IL-10-secreting blood cells that is corrected by interferon-beta (IFN-beta) treatment.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Low interleukin-10 production is associated with higher disability and MRI lesion load in secondary progressive multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

New diagnostic criteria for multiple sclerosis: guidelines for research protocols

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Influence of interferon beta-1a dose frequency on PBMC cytokine secretion and biological effect markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Interferon beta induces interleukin-10 expression: relevance to multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Clinical viral infections and multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

An investigation of polymorphism in the interleukin-10 gene promoter.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Interleukin 10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T cell proliferation by diminishing the antigen-presenting capacity of monocytes via downregulation of class II major histocompatibility complex expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Differential mechanisms of action of interferon-beta and glatiramer aetate in MS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

Viral infections trigger multiple sclerosis relapses: a prospective seroepidemiological study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1468-1331.2004.01102.X

10.1111/J.1468-1331.2004.01102.X

21 January 2018

Identifiers

DOI

1 reference

21 May 2018

PubMed ID

15693804

1 reference

21 May 2018